 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...25262728293031323334353637» |
- | Alecensa (alectinib) / Roche
Enrollment open, Metastases: ALERT-lung: ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 4, 2018
P2, N=44, Recruiting, Sponsor: European Thoracic Oncology Platform
Not yet recruiting --> Recruiting
- | Alecensa (alectinib) / Roche
Phase classification: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 21, 2018
P1/2, N=134, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Phase classification: P2 --> P1/2
- | Alunbrig (brigatinib) / Takeda
Trial initiation date, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - Aug 18, 2018
P2, N=103, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
Phase classification: P2 --> P1/2 Initiation date: Jun 2018 --> Oct 2018
- | Alunbrig (brigatinib) / Takeda
New trial, Metastases: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=400, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- | Alunbrig (brigatinib) / Takeda
Enrollment open, Metastases: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=400, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Jun 2018 --> Oct 2018 Not yet recruiting --> Recruiting
- | Alunbrig (brigatinib) / Takeda
Trial initiation date, Metastases: ALTA-3: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Aug 12, 2018
P3, N=246, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Aug 2018 --> Dec 2018
- | Zykadia (ceritinib) / Novartis
Trial completion, Trial completion date: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Jul 31, 2018
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Aug 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. (Pubmed Central) - Jul 25, 2018
Patients whose tumors harbor ALK rearrangements or fusions respond to treatment with crizotinib and alectinib, including tumors not normally associated with ALK mutations, such as non-Langerhans cell histiocytosis or renal cell carcinoma. Comprehensive genomic profiling using next-generation sequencing can detect targetable ALK fusions irrespective of tumor type or fusions partner.
- | Alunbrig (brigatinib) / Takeda
New P3 trial, Metastases: ALTA-3: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Jul 24, 2018
P3, N=246, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical, P2 data, Journal: Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. (Pubmed Central) - Jul 20, 2018
P1/2
Exploratory analysis showed that the occurrence of an objective response may be associated with a better HRQoL. Patients treated with alectinib in this phase II study achieved clinically meaningful improvements in HRQoL and symptoms and had delayed time to symptom deterioration.
- ||||| Alecensa (alectinib) / Roche
Trial initiation date: ALINA: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 29, 2018
P3, N=255, Not yet recruiting, Sponsor: Hoffmann-La Roche
Patients treated with alectinib in this phase II study achieved clinically meaningful improvements in HRQoL and symptoms and had delayed time to symptom deterioration. Initiation date: Jun 2018 --> Sep 2018
- | Alecensa (alectinib) / Roche
Clinical, P2 data, Journal: Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer. (Pubmed Central) - Jun 13, 2018
This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate. Alectinib also had an acceptable safety profile with a longer duration of follow-up.
- || Trial completion date, Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 1, 2018
P2a, N=600, Recruiting, Sponsor: Genentech, Inc.
Alectinib also had an acceptable safety profile with a longer duration of follow-up. Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- |||| Alunbrig (brigatinib) / Takeda
New P2 trial, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - May 27, 2018
P2, N=103, Not yet recruiting, Sponsor: Ariad Pharmaceuticals
- | Retrospective data, Review, Journal: Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. (Pubmed Central) - May 19, 2018
ALK inhibitors have an acceptable safety profile with a low risk of treatment-related deaths. Important differences in toxicity profile were detected amongst the different drugs.
- ||||| New P2 trial, PARP Biomarker, PD(L)-1 Biomarker: CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - Apr 12, 2018
P2, N=790, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Alecensa (alectinib) / Roche
Trial completion date, Metastases: ALEX: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (clinicaltrials.gov) - Mar 15, 2018
P3, N=303, Active, not recruiting, Sponsor: Hoffmann-La Roche
Important differences in toxicity profile were detected amongst the different drugs. Trial completion date: Dec 2017 --> Jan 2020
- |||| Alecensa (alectinib) / Roche
Trial completion, Trial primary completion date: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Mar 13, 2018
P2, N=138, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2017 --> Jan 2020 Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Oct 2017
- |||||||||| Alecensa (alectinib) / Roche
New P3 trial: ALINA: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 7, 2018
P3, N=255, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
New P2 trial, Metastases: ALERT-lung: ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 6, 2018
P2, N=44, Not yet recruiting, Sponsor: European Thoracic Oncology Platform
- |||| Alecensa (alectinib) / Roche
Trial primary completion date, Metastases: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 19, 2018
P3, N=187, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Oct 2017 Trial primary completion date: Dec 2019 --> Apr 2018
- | Alecensa (alectinib) / Roche
Clinical, Journal: Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-positive NSCLC Progressing on First Generation ALK Inhibitor. (Pubmed Central) - Jan 21, 2018
Over the last 2 years, our therapeutic armamentarium against genomically-defined subgroups of non-small cell lung cancer (NSCLC) has extended to patients with acquired resistance to front-line targeted therapy. Alectinib (Alecensa®, CH5424802), a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK), is indicated for patients with metastatic, ALK rearrangement-positive NSCLC whose disease has worsened after treatment with crizotinib or who became intolerant of the drug and it received orphan drug designation, breakthrough therapy designation, priority review status, and accelerated approval by the FDA.
- | Xalkori (crizotinib) / Pfizer
Journal: Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? (Pubmed Central) - Dec 29, 2017
Here we report an ALK+ NSCLC patient who had disease progression after ceritinib and then alectinib where an ALK G1202R mutation was detected on circulating tumor (ct) DNA prior to enrollment onto a trial of another next generation ALK inhibitor, lorlatinib...The patient was subsequently treated with carboplatin/etoposide and alectinib, but had rapid clinical deterioration and died...This case illustrates that multiple/compound resistance mechanisms to ALK inhibitors can occur and provide supporting information that loss of p53 and Rb1 are important in SCLC transformation. If clinically feasible, tissue-based re-biopsy allowing histological examination and CGP remains the gold standard to assess resistance mechanism(s) and to direct subsequent rational clinical care.
- ||| Alecensa (alectinib) / Roche
Enrollment open, Metastases: Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=167, Recruiting, Sponsor: Hoffmann-La Roche
If clinically feasible, tissue-based re-biopsy allowing histological examination and CGP remains the gold standard to assess resistance mechanism(s) and to direct subsequent rational clinical care. Not yet recruiting --> Recruiting
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. (Pubmed Central) - Nov 30, 2017
Among these, knocking down fibroblast growth factor receptor substrate 2 (FRS2) or coiled-coil and C2 domain-containing protein 1A (CC2D1A), both scaffolding proteins, sensitized multiple ALK fusion cell lines to the ALK inhibitors crizotinib and alectinib. Collectively, our data set provides a resource that enhances our understanding of signaling and drug resistance networks consequent to ALK fusions and identifies potential targets to improve the efficacy of ALK inhibitors in patients.
- | Alecensa (alectinib) / Roche
Journal: Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small-Cell Lung Cancer. (Pubmed Central) - Nov 3, 2017
Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies. In parallel, development of more selective, potent RET TKIs is warranted.
- | Trial initiation date: NCT Neuro Master Match - N (clinicaltrials.gov) - Nov 1, 2017
P1/2, N=350, Not yet recruiting, Sponsor: University Hospital Heidelberg
In parallel, development of more selective, potent RET TKIs is warranted. Initiation date: Jul 2017 --> Jan 2018
- | Journal: Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. (Pubmed Central) - Oct 29, 2017
These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors. Cancer Discov; 6(10); 1118-33.
- |||| Alecensa (alectinib) / Roche
Trial completion: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 25, 2017
P2, N=127, Completed, Sponsor: Hoffmann-La Roche
Cancer Discov; 6(10); 1118-33. Active, not recruiting --> Completed
- | Zykadia (ceritinib) / Novartis
Enrollment closed: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Oct 16, 2017
P2, N=20, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Enrollment open, Tumor mutational burden, IO Companion diagnostic, PD(L)-1 Biomarker, PD(L)-1 companion diagnostic, Metastases: BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 10, 2017
P2/3, N=580, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (Pubmed Central) - Sep 9, 2017
Not yet recruiting --> Recruiting Alectinib demonstrated promising efficacy in the CNS for ALK+ NSCLC patients pretreated with crizotinib, regardless of the assessment criteria used.
- ||| Alecensa (alectinib) / Roche
New trial, Metastases: Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=167, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
Journal: The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. (Pubmed Central) - Aug 27, 2017
Also, in the TH-MYCN transgenic mouse model, alectinib resulted in decreased tumor growth and prolonged survival time. These results indicate that alectinib may be a promising therapeutic agent for the treatment of NB.
- ||||| Alecensa (alectinib) / Roche
Enrollment closed, Metastases: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 17, 2017
P3, N=187, Active, not recruiting, Sponsor: Hoffmann-La Roche
These results indicate that alectinib may be a promising therapeutic agent for the treatment of NB. Recruiting --> Active, not recruiting
- | Retrospective data, Journal: Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. (Pubmed Central) - Aug 16, 2017
Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient)...Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.
- | Cotellic (cobimetinib) / Exelixis, Roche, Alecensa (alectinib) / Roche
Enrollment open, Metastases: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC (clinicaltrials.gov) - Aug 11, 2017
P1/2, N=31, Recruiting, Sponsor: Massachusetts General Hospital
Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients. Not yet recruiting --> Recruiting
- | Zykadia (ceritinib) / Novartis
Review, Journal: The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. (Pubmed Central) - Aug 10, 2017
The discovery of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011...There is now a next generation of ALK inhibitors, including two that have been approved-ceritinib and alectinib-and others that are in development-brigatinib, lorlatinib and X-396...Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation-driven tumors.
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Biomarker, Review, Journal: J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. (Pubmed Central) - Jul 29, 2017
Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation-driven tumors. No abstract available
- |||| Alecensa (alectinib) / Roche
Enrollment open: A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer (clinicaltrials.gov) - Jul 25, 2017
P1/2, N=78, Recruiting, Sponsor: Dana-Farber Cancer Institute
No abstract available Not yet recruiting --> Recruiting
- | Alecensa (alectinib) / Roche
Journal: Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (Pubmed Central) - Jul 23, 2017
P1/2
As previously reported, alectinib was well tolerated, regardless of baseline CNS disease. Conclusion Alectinib showed good efficacy against CNS metastases, in addition to systemic activity, in crizotinib-refractory ALK-positive NSCLC.
- |||||| Alecensa (alectinib) / Roche
Enrollment open: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (clinicaltrials.gov) - Jul 2, 2017
P3, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Conclusion Alectinib showed good efficacy against CNS metastases, in addition to systemic activity, in crizotinib-refractory ALK-positive NSCLC. Not yet recruiting --> Recruiting
- |||| Alecensa (alectinib) / Roche
Enrollment open: ATALK: A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 2, 2017
P2, N=73, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 29, 2017
P1b, N=52, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Alecensa (alectinib) / Roche
New P1/2 trial, Metastases: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC (clinicaltrials.gov) - Jun 29, 2017
P1/2, N=31, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Alecensa (alectinib) / Roche
Enrollment change: Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib (clinicaltrials.gov) - Jun 28, 2017
P1, N=28, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=48 --> 28
- |||||||||| Alecensa (alectinib) / Roche
New P3 trial: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (clinicaltrials.gov) - Jun 20, 2017
P3, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Alecensa (alectinib) / Roche
Trial primary completion date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 7, 2017
P2, N=127, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=48 --> 28 Trial primary completion date: May 2017 --> Oct 2014
- || Alecensa (alectinib) / Roche
Trial primary completion date: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Jun 7, 2017
P2, N=138, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2017 --> Oct 2014 Trial primary completion date: Aug 2015 --> Oct 2014
- |||||||||| New P2/3 trial, Tumor mutational burden, IO Companion diagnostic, PD(L)-1 Biomarker, PD(L)-1 companion diagnostic, Metastases: BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 7, 2017
P2/3, N=580, Not yet recruiting, Sponsor: Hoffmann-La Roche